Antimicrobial Agents and Chemotherapy · 2007 · 206 citations · 34 references
Life SciencesInfectious DiseasesMicrobiologyMedical MicrobiologyMicrobial GeneticsMicrobial PathogenesisBacterial EpidemiologyBacterial InfectionsPathogen GenomicsCeftriaxone TherapyEmergenceGenetic PolymorphismsGenomic Characterization Of PathogensGenotypic Characterization Of IsolatesHost Genetic PolymorphismsNeisserial SusceptibilitySingle-nucleotide Variants
The recent emergence and transmission of Neisseria gonorrhoeae isolates with reduced susceptibility to expanded-spectrum cephalosporins such as cefixime and ceftriaxone have been reported. The aim of this study was to determine the correlation of different polymorphisms in the penA, mtrR, porB1b (penB), and ponA genes of N. gonorrhoeae with reduced susceptibility to cefixime and ceftriaxone. Eighteen gonococcal isolates with reduced cefixime and ceftriaxone susceptibility (Cef(i)) and two susceptible isolates were characterized using serovar determination, antibiograms, N. gonorrhoeae multiantigen sequence typing (NG-MAST), and sequencing of penA, mtrR, porB1b, and ponA alleles. For the Cef(i) isolates (n = 18), the MICs of cefixime and ceftriaxone ranged between 0.032 to 0.38 mug/ml and 0.064 to 0.125 mug/ml, respectively. These isolates were assigned five different serovars and six divergent NG-MAST sequence types. Eleven isolates (61%) with higher MICs of cefixime and ceftriaxone contained a nearly identical penA mosaic allele and previously described polymorphisms in mtrR (a single nucleotide [A] deletion in the promoter), penB (mutations in porB1b encoding loop 3 of PorB1b), and ponA (ponA1 polymorphism). The remaining seven Cef(i) isolates (39%), which had somewhat lower MICs of cefixime and ceftriaxone, contained an aspartic acid insertion (Asp-345a) in PBP 2 in conjunction with alterations of 4 to 10 amino acid residues in the C-terminal region of the transpeptidase domain of penA. In conclusion, an unambiguous association between penA mosaic alleles, in conjunction with genetic polymorphisms in mtrR, porB1b, and ponA, and greater reduced susceptibility to cefixime and ceftriaxone was identified.
34
Satoshi Ameyama, Shoichi Onodera, Masahiro Takahata et al. · Antimicrobial Agents and Chemotherapy · 2002 · 228 citations · Full text
Masayasu Ito, Takashi Deguchi, Kohsuke Mizutani et al. · Antimicrobial Agents and Chemotherapy · 2004 · 206 citations · Full text
Patricia A. Ropp, Mei Hu, Melanie Olesky et al. · Antimicrobial Agents and Chemotherapy · 2002 · 189 citations · Full text